Upcoming Presentations, Tax Settlements, Prestigious Recognitions, and Share Price Updates - Research Report on Vertex, Teva, Perrigo, Novartis, and Cubist PR Newswire NEW YORK, November 20, 2013 NEW YORK, November 20, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Perrigo Company (NYSE: PRGO), Novartis AG (ADR) (NYSE: NVS) and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Vertex Pharmaceuticals Incorporated Research Report On November 11, 2013, Vertex Pharmaceuticals Incorporated (Vertex Pharmaceuticals) announced that the Company will present at the Deutsche Bank BioFEST in Boston, Massachusetts on December 2, 2013, at 2:50 p.m. ET. The Company added that the audio portion of the remarks can be accessed live through the "Investors" section of Vertex's website, under the "Events and Presentations" link. Vertex also informed that a replay of the conference call and its webcast will be archived on its website for seven days following the presentation. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e696_VRTX Teva Pharmaceutical Industries Ltd. (ADR) Research Report On November 11, 2013, Teva Pharmaceutical Industries Ltd. (ADR) (Teva) announced that the Company has reached an agreement with the Israel Tax Authority to pay NIS 2.5 billion (approximately $718 million, as per the exchange rate on November 10, 2013), for the release of trapped profits, settling tax assessments for 2005-2007, and applying similar principles through 2011. The Company said that it will pay approximately NIS 2 billion ($565 million) within the framework of amendment 69 to the Law for the Encouragement of Capital Investments (the "Trapped Profits Law"), which includes the payment of NIS 336 million ($95 million) made in May 2013. Teva added that it will also pay approximately NIS 840 million ($237 million) regarding tax assessments for 2005-2011. The Company expects to incur a charge of approximately $235 million to be reported in Q4 2013, which will be reflected in its non-GAAP results. The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e3a3_TEVA Perrigo Company Research Report On November 15, 2013, Perrigo Company's (Perrigo) stock rose 0.41%, ending the day at $153.13. Over the previous three trading sessions, shares of Perrigo gained 2.07%, compared to the S&P 500 which gained 1.72% during the same period. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/4168_PRGO Novartis AG (ADR) Research Report On November 15, 2013, Novartis AG (ADR) (Novartis) announced that the World Forum for Ethics in Business (WFEB) has awarded the Company the Ethics in Business Award in the Outstanding Corporation category. According to the Company, the Ethics in Business Awards recognizes individuals and companies that have demonstrated the importance of human values and ethics in business. On receiving this honor, Joseph Jimenez, CEO of Novartis, said, "This award recognizes our efforts in implementing Social Ventures, and building responsibility into our business, particularly in the developing world." Novartis informed that Novartis Social Ventures are innovative business models that build local, sustainable capabilities for healthcare around the world. The Full Research Report on Novartis AG (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9b6d_NVS Cubist Pharmaceuticals Inc. Research Report On November 17, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that it has been named one of the Top Places to Work in Massachusetts in an annual employee-based survey from The Boston Globe, marking the Company's 6^th consecutive year in the list. According to the Company, The Boston Globe's 2013 Top Places to Work Survey, conducted by employee survey firm WorkplaceDynamics, measured more than 76,000 individuals' responses to statements regarding six key factors related to employee happiness, including company direction, execution, employee connection, work load and responsibility, management, and pay and benefits. Cubist CEO Michael Bonney, said, "Being recognized as one of the Top Places to Work for six years in a row is a source of great pride for me personally and a reflection of the incredible people that make up our organization and the passion they bring to our mission. I'm pleased that we have continued to enhance our strong culture while experiencing tremendous growth this year as we build our international business and expand our pipeline." The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/92f2_CBST EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Upcoming Presentations, Tax Settlements, Prestigious Recognitions, and Share Price Updates - Research Report on Vertex, Teva,
Press spacebar to pause and continue. Press esc to stop.